Covered recipient · General Payments record
WEILY SOONG
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$93,885.24
259 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $39,850.00 | 19 |
| Consulting Fee | $39,626.50 | 20 |
| Travel and Lodging | $7,692.10 | 28 |
| Food and Beverage | $6,716.64 | 192 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $31,996.11 | 63 |
| AbbVie Inc. | $16,201.42 | 22 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $10,943.78 | 17 |
| UCB, Inc. | $9,920.00 | 6 |
| Genentech USA, Inc. | $8,565.57 | 28 |
| GlaxoSmithKline, LLC. | $5,292.58 | 20 |
| Amgen Inc. | $4,077.85 | 11 |
| Regeneron Healthcare Solutions, Inc. | $2,216.88 | 17 |
| GENZYME CORPORATION | $1,801.43 | 16 |
| PFIZER INC. | $1,325.09 | 12 |
| Takeda Pharmaceuticals U.S.A., Inc. | $260.99 | 12 |
| Glaukos Corporation | $154.06 | 1 |
| Teva Pharmaceuticals USA, Inc. | $150.70 | 2 |
| CSL Behring | $150.59 | 5 |
| BioCryst US Sales Co., LLC | $149.88 | 1 |
| Genentech, Inc. | $131.86 | 3 |
| LEO Pharma Inc. | $124.06 | 3 |
| Blueprint Medicines Corporation | $103.17 | 4 |
| Grifols USA, LLC | $90.38 | 4 |
| Octapharma USA, Inc. | $78.31 | 4 |
| Optinose US, Inc. | $65.67 | 4 |
| Lilly USA, LLC | $37.67 | 1 |
| Pharming Healthcare, Inc. | $17.81 | 1 |
| kaleo, Inc. | $15.76 | 1 |
| Merck Sharp & Dohme LLC | $13.62 | 1 |
Page 2 of 6; records 51–100 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
WEILY SOONG
NPI 1316981608 · CMS profile ID 286379
BIRMINGHAM, AL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 6; records 51–100 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1316981608?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- WEILY SOONG, NPI 1316981608, CMS profile ID 286379. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316981608?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). WEILY SOONG, NPI 1316981608, CMS profile ID 286379. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316981608?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- WEILY SOONG, NPI 1316981608, CMS profile ID 286379, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1316981608?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
259 matching records · $93,885.24 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 259.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $3,900.00 | 10/17/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001598875 | CMS |
| Genentech USA, Inc. | $25.86 | 10/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040596278 | CMS |
| Teva Pharmaceuticals USA, Inc. | $26.03 | 10/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056767769 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $34.95 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055615695 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $3.42 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055615701 | CMS |
| GlaxoSmithKline, LLC. | $11.17 | 10/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001599443 | CMS |
| Regeneron Healthcare Solutions, Inc. | $21.23 | 10/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999458719 | CMS |
| PFIZER INC. | $19.35 | 10/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050290477 | CMS |
| GlaxoSmithKline, LLC. | $13.32 | 10/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001599991 | CMS |
| AstraZeneca Pharmaceuticals LP | $76.16 | 09/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1024985795 | CMS |
| AstraZeneca Pharmaceuticals LP | $60.50 | 09/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025004229 | CMS |
| AstraZeneca Pharmaceuticals LP | $134.71 | 09/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1024983615 | CMS |
| AstraZeneca Pharmaceuticals LP | $659.48 | 09/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025002249 | CMS |
| AstraZeneca Pharmaceuticals LP | $194.77 | 09/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025028977 | CMS |
| AstraZeneca Pharmaceuticals LP | $265.75 | 09/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025034188 | CMS |
| AstraZeneca Pharmaceuticals LP | $127.64 | 09/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025023473 | CMS |
| AstraZeneca Pharmaceuticals LP | $56.96 | 09/28/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025025773 | CMS |
| Blueprint Medicines Corporation | $16.41 | 09/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051256367 | CMS |
| Genentech USA, Inc. | $22.42 | 09/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040596223 | CMS |
| Genentech USA, Inc. | $30.32 | 09/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040596219 | CMS |
| Genentech USA, Inc. | $25.99 | 09/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040596265 | CMS |
| LEO Pharma Inc. | $18.44 | 09/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053532733 | CMS |
| Merck Sharp & Dohme LLC | $13.62 | 09/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048647081 | CMS |
| AbbVie Inc. | $13.95 | 09/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999073203 | CMS |
| AbbVie Inc. | $3,500.00 | 09/18/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999073199 | CMS |
| Novartis Pharmaceuticals Corporation | $14.01 | 09/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993257923 | CMS |
| Amgen Inc. | $1,850.00 | 09/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020195369 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,850.00 | 09/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025024905 | CMS |
| GlaxoSmithKline, LLC. | $119.97 | 09/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001598124 | CMS |
| Novartis Pharmaceuticals Corporation | $1.05 | 09/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 993257917 | CMS |
| AbbVie Inc. | $25.85 | 09/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999073169 | CMS |
| AbbVie Inc. | $31.05 | 09/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999073175 | CMS |
| AbbVie Inc. | $361.80 | 09/12/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999073183 | CMS |
| AbbVie Inc. | $155.83 | 09/12/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999073189 | CMS |
| AbbVie Inc. | $874.35 | 09/12/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999073195 | CMS |
| AbbVie Inc. | $199.02 | 09/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999073159 | CMS |
| AbbVie Inc. | $163.85 | 09/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999073163 | CMS |
| Optinose US, Inc. | $18.77 | 09/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1035097769 | CMS |
| AstraZeneca Pharmaceuticals LP | $6,161.25 | 09/05/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025002697 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.96 | 09/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1024998811 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.72 | 09/01/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025014683 | CMS |
| AstraZeneca Pharmaceuticals LP | $45.00 | 09/01/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025019777 | CMS |
| PFIZER INC. | $15.34 | 09/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050023061 | CMS |
| Amgen Inc. | $125.00 | 08/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020195365 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 08/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025057811 | CMS |
| GENZYME CORPORATION | $23.80 | 08/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049939567 | CMS |
| AbbVie Inc. | $2,500.00 | 08/22/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999073151 | CMS |
| AbbVie Inc. | $10.52 | 08/22/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999073155 | CMS |
| PFIZER INC. | $19.26 | 08/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049961381 | CMS |
| AbbVie Inc. | $124.99 | 08/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999073143 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,970.55 | 2 |
| PY2025 | Principal investigator | $536,363.96 | 267 |
| PY2024 | Recipient | $428.00 | 2 |
| PY2024 | Principal investigator | $649,845.66 | 342 |
| PY2023 | Recipient | $3,077.41 | 5 |
| PY2023 | Principal investigator | $340,262.11 | 133 |
| PY2022 | Recipient | $21,729.66 | 15 |
| PY2022 | Principal investigator | $328,811.41 | 129 |
| PY2021 | Recipient | $13,581.28 | 16 |
| PY2021 | Principal investigator | $792,044.99 | 199 |
| PY2020 | Recipient | $44,172.37 | 14 |
| PY2020 | Principal investigator | $1,149,340.73 | 231 |
| PY2019 | Recipient | $135,778.06 | 80 |
| PY2019 | Principal investigator | $968,608.31 | 161 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
269 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Incyte Corporation | $1,927.20 | 12/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240517349 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,097.00 | 12/22/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226136517 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 12/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184279016 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 12/16/2025 | Non-covered Recipient Entity AllerVie Clinical Research | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228815666 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 12/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202530504 |
| Principal investigator 1 | Incyte Corporation | $176.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240517362 |
| Principal investigator 1 | Incyte Corporation | $73.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240517422 |
| Principal investigator 1 | Incyte Corporation | $11.95 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240517435 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240517469 |
| Principal investigator 1 | Incyte Corporation | $5,000.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240517474 |
| Principal investigator 1 | Incyte Corporation | $232.00 | 12/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240517478 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 12/08/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226136481 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 12/08/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136497 |
| Principal investigator 1 | Incyte Corporation | $3,166.00 | 12/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240517390 |
| Principal investigator 1 | Incyte Corporation | $1,450.00 | 12/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents 6 to less than 18 Years Old With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240517445 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,297.43 | 12/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1192156872 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,564.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN | No dispute reported | 06/30/2026 | 1192156877 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517413 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 12/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517426 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12.70 | 11/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184264503 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $146.71 | 11/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184264505 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.40 | 11/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184264507 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $358.80 | 11/17/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136460 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,496.00 | 11/17/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136463 |
| Principal investigator 1 | Incyte Corporation | $20.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517353 |
| Principal investigator 1 | Incyte Corporation | $6.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517357 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517366 |
| Principal investigator 1 | Incyte Corporation | $169.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517369 |
| Principal investigator 1 | Incyte Corporation | $169.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517374 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517378 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517382 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517387 |
| Principal investigator 1 | Incyte Corporation | $322.20 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517395 |
| Principal investigator 1 | Incyte Corporation | $135.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517399 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517404 |
| Principal investigator 1 | Incyte Corporation | $240.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517408 |
| Principal investigator 1 | Incyte Corporation | $180.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517417 |
| Principal investigator 1 | Incyte Corporation | $128.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517430 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517440 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517449 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517453 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517458 |
| Principal investigator 1 | Incyte Corporation | $202.50 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517462 |
| Principal investigator 1 | Incyte Corporation | $120.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517465 |
| Principal investigator 1 | Incyte Corporation | $45.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517482 |
| Principal investigator 1 | Incyte Corporation | $45.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517486 |
| Principal investigator 1 | Incyte Corporation | $45.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517489 |
| Principal investigator 1 | Incyte Corporation | $45.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517493 |
| Principal investigator 1 | Incyte Corporation | $68.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517497 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517500 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517505 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 11/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517509 |
| Principal investigator 1 | ABBVIE INC. | $1,313.55 | 11/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202522873 |
| Principal investigator 1 | ABBVIE INC. | $80.00 | 11/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202522935 |
| Principal investigator 1 | ABBVIE INC. | $3,300.00 | 11/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202522937 |
| Principal investigator 1 | ABBVIE INC. | $25.00 | 11/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202522939 |
| Principal investigator 1 | ABBVIE INC. | $433.00 | 11/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202521087 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $409.93 | 10/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252586 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $423.90 | 10/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252588 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $264.82 | 10/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252590 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.07 | 10/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252592 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $529.03 | 10/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252594 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $227.71 | 10/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252596 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.80 | 10/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252598 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $263.88 | 10/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252600 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $146.71 | 10/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252602 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.47 | 10/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252604 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $789.26 | 10/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252606 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,238.92 | 10/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252608 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,310.00 | 10/20/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226136436 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,978.00 | 10/14/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 10/13/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184249847 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 10/13/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184249849 |
| Principal investigator 1 | ABBVIE INC. | $392.00 | 10/09/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202514267 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,238.92 | 10/09/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184248952 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/03/2025 | Non-covered Recipient Entity AllerVie Clinical Research | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228825601 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $60.00 | 09/29/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226136402 |
| Principal investigator 1 | PFIZER INC. | $1,273.14 | 09/24/2025 | Non-covered Recipient Entity AllerVie Clinical Research | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228835544 |
| Recipient | Amgen Inc. | $2,030.55 | 09/22/2025 | Covered Recipient Physician | A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE) | No dispute reported | 06/30/2026 | 1246636938 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $770.00 | 09/15/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226136348 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,465.50 | 09/15/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136388 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,858.00 | 09/15/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136393 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $445.00 | 09/15/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226136399 |
| Principal investigator 1 | Incyte Corporation | $20.00 | 09/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517315 |
| Principal investigator 1 | Incyte Corporation | $10.00 | 09/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517333 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $185.42 | 09/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235165 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $120.00 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226136345 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136352 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $235.00 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136357 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $327.60 | 09/03/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136367 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,681.00 | 08/25/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226136383 |
| Principal investigator 1 | Incyte Corporation | $1,312.20 | 08/13/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517329 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $700.00 | 08/11/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136334 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,892.00 | 08/11/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136342 |
| Principal investigator 1 | ABBVIE INC. | $2,310.20 | 08/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202501632 |
| Principal investigator 1 | PFIZER INC. | $3,216.10 | 08/05/2025 | Non-covered Recipient Entity AllerVie Clinical Research | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228844208 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 07/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184217481 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $500.00 | 07/18/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama, LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049611 |
| Principal investigator 1 | ABBVIE INC. | $245.00 | 07/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202498708 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $53,200.70 | 07/14/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136275 |
| Principal investigator 1 | ABBVIE INC. | $433.00 | 07/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202495885 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 07/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517319 |
| Principal investigator 1 | Incyte Corporation | $20.00 | 07/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517323 |
| Principal investigator 1 | Incyte Corporation | $169.00 | 07/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517337 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 07/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517340 |
| Principal investigator 1 | Incyte Corporation | $94.50 | 07/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517344 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $427.53 | 07/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184212485 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $427.53 | 07/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184212487 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $140.00 | 07/02/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226136312 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $22,488.18 | 07/01/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190310446 |
| Principal investigator 1 | PFIZER INC. | $2,256.59 | 06/26/2025 | Non-covered Recipient Entity AllerVie Clinical Research | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228851666 |
| Principal investigator 1 | Incyte Corporation | $1,970.00 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517278 |
| Principal investigator 1 | Incyte Corporation | $1,115.20 | 06/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517307 |
| Principal investigator 1 | Eli Lilly and Company | $20,725.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CTR OF ALABAMA, LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187879125 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184206813 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184206815 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184206819 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184206821 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184206823 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184206825 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184206827 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184206829 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184206833 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184206835 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207341 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207367 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $20.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207581 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $20.00 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184207585 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $320.00 | 06/16/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226136268 |
| Principal investigator 1 | PFIZER INC. | $1,600.00 | 05/30/2025 | Non-covered Recipient Entity AllerVie Clinical Research | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228857238 |
| Principal investigator 1 | PFIZER INC. | $1,883.31 | 05/29/2025 | Non-covered Recipient Entity AllerVie Clinical Research | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228857294 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,240.00 | 05/27/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226136265 |
| Principal investigator 1 | PFIZER INC. | $1,571.50 | 05/14/2025 | Non-covered Recipient Entity Clinical Research Center of Alabama | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228857231 |
| Principal investigator 1 | Incyte Corporation | $1,283.40 | 05/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517291 |
| Principal investigator 1 | ABBVIE INC. | $1,073.70 | 05/06/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202482141 |
| Principal investigator 1 | PFIZER INC. | $1,881.59 | 05/06/2025 | Non-covered Recipient Entity AllerVie Clinical Research | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228857222 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $140.00 | 05/05/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226136206 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $45.00 | 05/05/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226136210 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,654.90 | 05/05/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226136216 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $427.53 | 04/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184190235 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,285.00 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136224 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $360.00 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226136228 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $193.00 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136232 |
| Principal investigator 1 | ABBVIE INC. | $225.00 | 04/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202478930 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 04/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202478934 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 04/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240517258 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,110.00 | 04/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA | No dispute reported | 06/30/2026 | 1185554799 |
| Principal investigator 1 | Eli Lilly and Company | $231.30 | 04/23/2025 | Non-covered Recipient Entity THE OHIO STATE UNIVERSITY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187892824 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14.00 | 04/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184184788 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.00 | 04/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184184790 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $13,250.00 | 04/17/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama, LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049613 |
| Principal investigator 1 | Incyte Corporation | $972.60 | 04/14/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517269 |
| Principal investigator 1 | Incyte Corporation | $1,426.00 | 04/14/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517283 |
| Principal investigator 1 | Incyte Corporation | $1,970.00 | 04/14/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517287 |
| Principal investigator 1 | PFIZER INC. | $25.00 | 04/08/2025 | Non-covered Recipient Entity AllerVie Clinical Research | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228859841 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $68.20 | 04/08/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama, LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049641 |
| Principal investigator 1 | Eli Lilly and Company | $4,000.00 | 04/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CTR OF ALABAMA, LLC | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 3 EFFICACY AND SAFETY STUDY OF LEBRIKIZUMAB/ LY3650150 IN ADULTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS ON A BACKGROUND THERAPY WITH INTRANASAL CORTICOSTEROIDS | No dispute reported | 06/30/2026 | 1187875773 |
| Principal investigator 1 | Incyte Corporation | $21.12 | 04/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517274 |
| Principal investigator 1 | Incyte Corporation | $1.96 | 04/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517295 |
| Principal investigator 1 | Incyte Corporation | $1.92 | 04/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517299 |
| Principal investigator 1 | Incyte Corporation | $57.25 | 04/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517303 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 04/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517311 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,522.20 | 04/02/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226136168 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,364.50 | 03/24/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226136156 |
| Principal investigator 1 | PFIZER INC. | $4,026.00 | 03/22/2025 | Non-covered Recipient Entity AllerVie Clinical Research | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228862367 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,236.50 | 03/17/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136196 |
| Principal investigator 1 | Incyte Corporation | $990.00 | 03/14/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517090 |
| Principal investigator 1 | Incyte Corporation | $1,458.00 | 03/14/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517098 |
| Principal investigator 1 | Incyte Corporation | $1,476.00 | 03/14/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517109 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $60.00 | 03/13/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama, LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049615 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517040 |
| Principal investigator 1 | Incyte Corporation | $36.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517045 |
| Principal investigator 1 | Incyte Corporation | $20.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517050 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517053 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517057 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517075 |
| Principal investigator 1 | Incyte Corporation | $10.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517083 |
| Principal investigator 1 | Incyte Corporation | $18.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517088 |
| Principal investigator 1 | Incyte Corporation | $94.50 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517105 |
| Principal investigator 1 | Incyte Corporation | $180.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517113 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517122 |
| Principal investigator 1 | Incyte Corporation | $127.56 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517125 |
| Principal investigator 1 | Incyte Corporation | $169.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517129 |
| Principal investigator 1 | Incyte Corporation | $45.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517134 |
| Principal investigator 1 | Incyte Corporation | $45.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517139 |
| Principal investigator 1 | Incyte Corporation | $72.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517144 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517148 |
| Principal investigator 1 | Incyte Corporation | $180.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517152 |
| Principal investigator 1 | Incyte Corporation | $180.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517156 |
| Principal investigator 1 | Incyte Corporation | $152.10 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517221 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517229 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517234 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517244 |
| Principal investigator 1 | Incyte Corporation | $512.50 | 03/06/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240517036 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,417.90 | 03/04/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226136192 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 03/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517199 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,873.82 | 02/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy | No dispute reported | 06/30/2026 | 1190303283 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $204.60 | 02/24/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama, LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049639 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 02/20/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240517513 |
| Principal investigator 1 | Incyte Corporation | $1,426.00 | 02/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517078 |
| Principal investigator 1 | Incyte Corporation | $1,250.60 | 02/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517094 |
| Principal investigator 1 | Incyte Corporation | $1,426.00 | 02/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517116 |
| Principal investigator 1 | Incyte Corporation | $1,970.00 | 02/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517225 |
| Principal investigator 1 | Incyte Corporation | $1,554.00 | 02/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517240 |
| Principal investigator 1 | Eli Lilly and Company | $14,549.00 | 02/18/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CTR OF ALABAMA, LLC | A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187878239 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $600.00 | 02/18/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226136164 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,534.00 | 02/18/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps | No dispute reported | 06/30/2026 | 1226136188 |
| Principal investigator 1 | Incyte Corporation | $548.08 | 02/12/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240517266 |
| Principal investigator 1 | ABBVIE INC. | $4,110.40 | 02/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202445381 |
| Principal investigator 1 | PFIZER INC. | $13,570.28 | 02/05/2025 | Non-covered Recipient Entity AllerVie Clinical Research | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228835514 |
| Recipient | PFIZER INC. | $940.00 | 01/28/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228821645 |
| Principal investigator 1 | Eli Lilly and Company | $48.13 | 01/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CTR OF ALABAMA, LLC | A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187879123 |
| Principal investigator 1 | Incyte Corporation | $4,891.26 | 01/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240517262 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,847.70 | 01/21/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama LLC | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226136140 |
| Principal investigator 1 | Incyte Corporation | $1,554.00 | 01/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517061 |
| Principal investigator 1 | Incyte Corporation | $1,476.00 | 01/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517067 |
| Principal investigator 1 | Incyte Corporation | $2,098.00 | 01/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517071 |
| Principal investigator 1 | Incyte Corporation | $1,104.80 | 01/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517102 |
| Principal investigator 1 | Incyte Corporation | $1,554.00 | 01/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517237 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $978.94 | 01/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184148107 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $42,064.80 | 01/16/2025 | Non-covered Recipient Entity ALLERVIE HEALTH | The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod | No dispute reported | 06/30/2026 | 1185554803 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 01/15/2025 | Non-covered Recipient Entity Clinical Research Center of Alabama | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228862692 |
| Principal investigator 1 | Incyte Corporation | $46.60 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501644 |
| Principal investigator 1 | Incyte Corporation | $11.40 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501649 |
| Principal investigator 1 | Incyte Corporation | $98.98 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501652 |
| Principal investigator 1 | Incyte Corporation | $9.18 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501656 |
| Principal investigator 1 | Incyte Corporation | $6.60 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501659 |
| Principal investigator 1 | Incyte Corporation | $12.96 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501664 |
| Principal investigator 1 | Incyte Corporation | $2.40 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501668 |
| Principal investigator 1 | Incyte Corporation | $74.64 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501673 |
| Principal investigator 1 | Incyte Corporation | $18.64 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501678 |
| Principal investigator 1 | Incyte Corporation | $12.12 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501682 |
| Principal investigator 1 | Incyte Corporation | $16.31 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501685 |
| Principal investigator 1 | Incyte Corporation | $3.00 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501689 |
| Principal investigator 1 | Incyte Corporation | $149.28 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501693 |
| Principal investigator 1 | Incyte Corporation | $32.62 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501698 |
| Principal investigator 1 | Incyte Corporation | $74.64 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501701 |
| Principal investigator 1 | Incyte Corporation | $37.32 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501705 |
| Principal investigator 1 | Incyte Corporation | $2.16 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501709 |
| Principal investigator 1 | Incyte Corporation | $1.20 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501713 |
| Principal investigator 1 | Incyte Corporation | $4.66 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501717 |
| Principal investigator 1 | Incyte Corporation | $6.99 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501720 |
| Principal investigator 1 | Incyte Corporation | $52.48 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501724 |
| Principal investigator 1 | Incyte Corporation | $279.90 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501729 |
| Principal investigator 1 | Incyte Corporation | $4.20 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501733 |
| Principal investigator 1 | Incyte Corporation | $5.40 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501737 |
| Principal investigator 1 | Incyte Corporation | $5.40 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501740 |
| Principal investigator 1 | Incyte Corporation | $5.40 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501744 |
| Principal investigator 1 | Incyte Corporation | $4.32 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501748 |
| Principal investigator 1 | Incyte Corporation | $52.48 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501752 |
| Principal investigator 1 | Incyte Corporation | $52.48 | 01/09/2025 | Non-covered Recipient Entity ALLERVIE CLINICAL RESEARCH | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma | No dispute reported | 06/30/2026 | 1240501755 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,000.00 | 01/09/2025 | Non-covered Recipient Entity Clinical Research Center Of Alabama, LLC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244049617 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $52,813.40 | 01/08/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Multicentre,Randomised,Double Blind,Parallel Group,Placebo Controlled,52 week,Phase 3,Efficacy and Safety Study of Tezepelumab in 5 to 12 Year Old Children with Severe Uncontrolled Asthma HORIZON | No dispute reported | 06/30/2026 | 1185554801 |
| Principal investigator 1 | Incyte Corporation | $80.15 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517162 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517166 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517170 |
| Principal investigator 1 | Incyte Corporation | $9.80 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517175 |
| Principal investigator 1 | Incyte Corporation | $115.70 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517179 |
| Principal investigator 1 | Incyte Corporation | $48.00 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517184 |
| Principal investigator 1 | Incyte Corporation | $99.12 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517188 |
| Principal investigator 1 | Incyte Corporation | $15.26 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517191 |
| Principal investigator 1 | Incyte Corporation | $15.26 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517195 |
| Principal investigator 1 | Incyte Corporation | $15.26 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517203 |
| Principal investigator 1 | Incyte Corporation | $24.78 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517207 |
| Principal investigator 1 | Incyte Corporation | $13.44 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517211 |
| Principal investigator 1 | Incyte Corporation | $13.44 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517214 |
| Principal investigator 1 | Incyte Corporation | $4.80 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517218 |
| Principal investigator 1 | Incyte Corporation | $15.26 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH CENTER OF ALABAMA | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240517253 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,656.30 | 01/01/2025 | Non-covered Recipient Entity ALABAMA ALLERGY AND ASTHMA CENTER | A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy | No dispute reported | 06/30/2026 | 1190308336 |